Sensorion has filed clinical trial applications in Canada and France for SENS-601, its AAV-based gene therapy targeting GJB2 mutations — the most common genetic cause of congenital deafness — while discontinuing development of its OTOF-targeting program, SENS-501....
No actionable change — this is an early-stage clinical trial application with no human efficacy or safety data yet; audiologists should monitor pipeline progress but cannot act on this clinically.
GJB2 mutations are the most frequent genetic cause of congenital deafness, so a successful AAV gene therapy could eventually offer a biological treatment option for a large portion of patients with hereditary hearing loss.
- 01Sensorion filed clinical trial applications (CTAs) for SENS-601 in Canada and France.
- 02SENS-601 is an AAV-based gene therapy targeting GJB2 mutations, the most common cause of genetic deafness.
- 03The company simultaneously discontinued its earlier OTOF-targeting program, SENS-501.
- 04No human trial data yet — SENS-601 is at the application/pre-trial stage.
- 05GJB2-related hearing loss represents a large potential patient population for gene therapy.
GJB2 mutations are the most common genetic cause of congenital deafness.
guidelinesupportedSENS-601 is an AAV-based gene therapy capable of targeting GJB2 mutations.
press releaseunclearSensorion filed clinical trial applications for SENS-601 in Canada and France.
press releasesupportedSensorion discontinued its OTOF-targeting SENS-501 program.
press releasesupported